07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Teva sales and marketing update

Teva launched 6.25 and 12.5 mg almotriptan tablets in the U.S. to treat migraines. The oral selective serotonin (5-HT1D) receptor agonist is a generic of Axert from Almirall S.A. (Madrid:ALM, Barcelona, Spain)....
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co.'s 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes it...
07:00 , Jul 7, 2008 |  BioCentury  |  Product Development

Cleaner than triptans

Triptans are the drug of choice for migraine patients, but they have cardiovascular side effects that leave many healthy patients wary and make them contraindicated for patients with CV disease. Merck & Co. Inc. disclosed...
07:00 , Oct 29, 2007 |  BioCentury  |  Product Development

Tezampanel vs. triptans

Tezampanel vs. triptans Compound [target] Study Dose Patient no. 2 hr headache response Tezampanel [AMPA/kainate receptor] (TorreyPines) Ph IIb 100 mg SC 77 57% (p=NS) 70 mg SC 74 64% (p=NS) 40 mg SC...
07:00 , Oct 8, 2007 |  BioCentury  |  Regulation

Significant isn't meaningful

Despite meeting the primary endpoints in two Phase III trials, last week Frova frovatriptan was deemed not approvable to prevent menstrual migraine. In yet another sign that FDA is moving the goalposts on product approvals,...
07:00 , Aug 8, 2005 |  BioCentury  |  Product Development

Marketed migraine drugs

Marketed migraine drugs Company Product Description 2004 sales AstraZeneca Zomig zolmitriptan (A) Serotonin 5-HT1B/1D receptor agonist $356M GlaxoSmithKline Imitrex sumatriptan (B) Serotonin 5-HT1 receptor agonist £682M ($1.3B) Johnson & Johnson Topamax topiramate Sulfamate-substituted monosaccharide that...
07:00 , Apr 21, 2003 |  BC Week In Review  |  Company News

Almirall Prodesfarma S.A., J&J sales and marketing update

JNJ's Ortho-McNeil Pharmaceutical Inc. and Janssen-Ortho Inc. units received U.S. and Canadian marketing rights to Almirall's Axert almotriptan to treat migraine. The compound previously was licensed to Pharmacia Corp. (PHA, Peapack, N.J.),...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

Triptans: Marketed

Researchers published in The Lancet results of a meta-analysis of 53 clinical trials of 7 triptans in 24,089 patients with migraine headaches. According to the analysis, rizatriptan, eletriptan and almotriptan gave patients the greatest relief...
07:00 , May 14, 2001 |  BC Week In Review  |  Clinical News

Axert almotriptan tablets regulatory update

The FDA granted marketing approval for Axert to treat acute migraine with or without aura in adults. Pharmacia Corp. (PHA), Peapack, N.J.   Product: Axert almotriptan tablets   Business: Pharmaceuticals, Neurological   ...
07:00 , May 8, 2000 |  BC Week In Review  |  Clinical News

Axert almotriptan: Phase III data; NDA under review; marketed in Spain

In a 1,173-patient Phase III trial, 58 percent of patients given a single dose of 12.5 mg Axert had pain relief after 2 hours versus 57 percent for patients given 50 mg of Glaxo...